Pall — Q1 FY2014 Earnings Presentation
16 slides from Pall's earnings presentation, Nov 26, 2013
Slide 1: Q1 FY 2014 Financial Results
Better Lives. Better Planet.SM © 2013 Pall Corporation Q1 FY 2014 Financial Results November 26, 2013 Exhibit 99.2
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the first quarter of fiscal year 2014 are preliminary until our Form 10-Q is filed with the Securities and Exchange Commission on or befor
Slide 3: Conference Call Information
3 Conference Call Information Dial-In Toll-Free: 855.356.7268 International: 706.634.1981 Replay Toll-Free: 855.859.2056 International: 404.537.3406 Conference ID: 97753933 Internet: www.pall.com/investor
Slide 4: Q1 Overview
4 Q1 Overview Q1 performance: as expected End markets and trends: improving FY 2014: – On plan – Operational execution continuing – Cost actions proceeding Executing in a challenging environment All remarks in this presentation are on a “Continuing Operations” basis, which excludes the results
Slide 5: Q1 Financial Summary
5 $628 $630 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2013 FY 2014 Q1 Financial Summary Dollars in millions, except EPS data A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix. 17.3% 17.1% 10.0% 15.0% 20.0% Operat
Slide 6: Q1 Sales by Segment
6 Life Sciences Consumables $295 +7% Industrial Consumables $255 -5% Industrial Systems $56 +8% Life Sciences Systems $24 -1% 40% 47% 9% 4% Q1 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts represent pe
Slide 7: Q1 Life Sciences Segment Performance
7 Q1 Life Sciences Segment Performance Dollars in millions excluding FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix 0% 30% 60% 57.1% -160 bps 58.7% 0% 30% 60% 22.9% -40 bps 23.3% FY 2013 FY 2014 Gross Margin Segment Marg
Slide 8: Q1 Industrial Segment Performance
8 Q1 Industrial Segment Performance Dollars in millions excluding FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix Gross Margin Segment Margin Process Technologies consumables: -15% Aerospace consumables: +5% Microel
Slide 9: Q1 Cash Flow and Working Capital
9 Q1 Cash Flow and Working Capital YTD FY14 YTD FY13 Operating Cash Flow 86$ 39$ CapEx (19) (23) Free Cash Flow 67$ 16$ Other Significant Sources/(Uses) of Cash: Proceeds from sale of assets - 536$ Acquisition of businesses (1) - Dividends (28) (24) Borrowing/Repayment under Financing Facilities 85
Slide 10: FY 2014 Outlook
10 Total Revenue Low to mid single digit growth Segment Revenue Life Sciences: Mid to high single digit growth Industrial: Flat −Modest consumables growth Pro Forma EPS $3.30 – $3.50 Represents growth of 9% – 15% Estimate excludes Discrete Items, future acquisitions and related costs FY
Slide 11: Appendix
Better Lives. Better Planet.SM © 2013 Pall Corporation Appendix
Slide 12: Q1 Earnings and FY 2014 Estimates Reconciliation
12 Appendix: Q1 Earnings and FY 2014 Estimates from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.63$ 0.77$ 3.33$ Discrete Items: ROTC after pro forma tax effect 0.07 0.03 0.07 Tax Adjustments - (0.09) - Interest Adjustments
Slide 13: Q1 Life Sciences Sales By Market & Technology Reconciliation
13 Appendix: Q1 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q1 FY14 Q1 FY14 Estimated Impact of FX Q1 FY14 Estimate Excluding FX Q1 FY13 % Change Excluding FX Consumables Sales: BioPharmaceuticals 196,118$ (989)$ 197,107$ 187,241$ 5.3% Food & Beverage 43,
Slide 14: Q1 Industrial Sales By Market & Technology Reconciliation
14 Appendix: Q1 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q1 FY14 Q1 FY14 Estimated Impact of FX Q1 FY14 Estimate Excluding FX Q1 FY13 % Change Excluding FX Consumables Sales: Process Technologies 125,078$ (1,829)$ 126,907$ 149,969$ -15.4% Aerospace 58,771
Slide 15: Q1 Orders by Segment Reconciliation
15 Appendix: Q1 Orders by Segment Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q1 FY14 Q1 FY14 Estimated Impact of FX Q1 FY14 Estimate Excluding FX Q1 FY13 % Change Excluding FX Life Sciences Orders: Consumables 299,140$ (1,635)$ 300,775$ 288,784$ 4.2% Systems 29,995 (959) 30,9
Slide 16: Q1 Operating Profit Reconciliation
16 Appendix: Q1 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q1 FY14 Q1 FY13 Life Sciences segment profit 73,045$ 69,842$ Industrial segment profit 50,482 52,766 Total segment profit 123,527$ 122,608$ General corporate expenses (15,964) (14,065) Operating profit 10